Regulation about coding for CytoSorb in Switzerland

On December 20, 2021, the tariff partners of the novel TARDOC reimbursement system for outpatient care (association of health insurers curafutura and association of physicians, FMH) re-submitted the substantially revised version 1.3 of TARDOC to the Federal Council. The tariff partners hope that the Federal Council will assess the new reimbursement system in the first quarter of 2022 and that it could be implemented from January 2023.

In 2015, the Federal Office for Public Health launched an HTA program intending to reassess the benefits already reimbursed by compulsory health insurance. The following ongoing re-evaluations are in progress: multigene expression tests in breast cancer, cardiac catheterization for coronary artery disease, invasive procedures for coronary artery disease, removal of osteosynthesis materials, etc.

On July 30, 2021, the Swiss Federal Statistics Office (UFS) published the 2022 version of the procedure code (CHOP) nomenclature in the German language. The newly introduced codes concern various technology groups, such as cardiovascular, gastrointestinal, neurology, interventional radiology, orthopedics, gynecology, and others.

On June 30, 2021, the Swiss Federal Council announced that the TARDOC outpatient tariff structure, presented by the association of insurers curafutura and the Swiss Medical Association (FMH), cannot be approved at this point. The Federal Council found the TARDOC tariff structure to have many drawbacks. Curafutura released an announcement in which they state that they will continue working on the TARDOC tariff structure and will try to implement as many changes as possible, according to the FOPH recommendations. This means that the TARDOC tariff structure is not likely to be implemented before January 2023.

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).